First, we examined the effects of an IL-17A-neutralizing antibody (α-IL-17A) and recombinant mouse IL-17A (rm-IL-17A) on tumor growth kinetics in the ICI-sensitive MT/ret-derived primary cutaneous melanoma (CM) mouse model (human ret transgene, BRAF-WT20). This evidence concerns the gene RET and cutaneous melanoma.